NEW YORK, NY / ACCESSWIRE / November 21, 2017 / U.S. markets edged higher Monday as investors focus shifted back towards corporate earnings and potential tax cuts. The Dow Jones Industrial Average gained 0.31 percent to close at 23,430.33, while the S&P 500 Index rose 0.13 percent to close at 2,582.14. The Nasdaq Composite Index increased 0.12 percent to close at 6,790.71.
“Market sentiment has grown less positive in recent weeks, with investors more concerned about tax policy, fuller valuations and a sense of complacency. From a fundamental perspective, investors are also becoming worried about the flattening yield curve and high yield market weakness, which tend to be bearish signals for equities,” said Robert Doll, chief equity strategist at Nuveen Asset Management LLC, in his weekly outlook, according to MarketWatch. “But we think the two most important drivers of equity markets — corporate earnings and real growth levels — still support a risk-on investment stance.”
RDI Initiates Coverage on:
Repros Therapeutics Inc.
Incyte Corporation's stock moved 6.18% lower Monday, to close the day at $98.95. The stock recorded a trading volume of 2,526,477 shares, which was above its three months average volume of 1,783,481 shares. In the last year, Incyte Corporation's shares have traded in a range of 98.49 - 153.15. The stock is currently trading 35.39% below its 52-week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $111.15 is below its 200-day moving average of $122.43. Shares of Incyte have fallen roughly 13.35 percent in the past month and are down 1.32 percent year-to-date.
Access RDI's Incyte Corporation Research Report at:
On Monday, shares in Repros Therapeutics Inc. recorded a trading volume of 1,416,248 shares, which was above the three months average volume of 1,154,892 shares. The stock ended the day 13.16% higher at 0.43. The share price has gained 65.38% from its 52-week low with a 52-week trading range of 0.26 - 2.00.The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.48 is greater than its 200-day moving average of $0.44. Shares of Repros Therapeutics have fallen roughly 23.75 percent in the past month and are down 67.42 percent year-to-date.
Access RDI's Repros Therapeutics Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.